Search results for " titers"
Article
Challenges of Protein Aggregation During Purification
While most aggregates are formed during upstream operations, and the risk for aggregate formation at the cellular level has increased as titers have increased, if unsuitable conditions are selected fo…
Article
Pharma Investments Reflect Key Industry Trends
First is the shift to biologic-based drugs, which has occurred along with a dramatic increase in the productivity, mainly in terms of much higher titers, of biopharmaceutical processes. “While demand …
Article
A Q&A With Parrish Galliher About Adopting Single-Use Systems
There are other factors that are helping to mitigate the risk as well—smaller markets, increased titers and improved processes help shrink plant-sizes ten-fold. And, since single-use facilities are sm…
Article
Q&As with Industry Leaders
… Cytiva
Cell Culture Media Considerations and Optimization for Improved Titers and Protein Quality
Peggy Lio, Senior Director of Global Cell Culture Servic…
Article
Raw Material Variability
The biopharmaceutical industry is developing a new approach to controlling variability in raw materials.
It would seem that raw materials used in bioprocessing operations are a relatively straig…
Article
Predicting Progress in Protein Aggregation
“Cells may stop secreting a protein if it takes on a new, aggregated form, leading to low titers and reduced yields and productivity. In addition, the formation of larger precipitates can cause the ph…
Article
Best Practices in Adopting Single-Use Systems
Moreover, the 5- to 10-fold improvement in product titers for monoclonal antibodies over the past 15 years has nearly eliminated arguments against single-use based on scale. Bioprocessors can now gene…
Article
QbD and PAT in Upstream and Downstream Processing
To gain perspective on the implementation of quality by design (QbD) and process analytical technology (PAT) in biopharmaceutical processing, BioPharm International spoke with Clinton Weber, as…